Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Patient Profile 1: Advanced HCC Treated with Durvalumab + Tremelimumab

February 20th 2023

Expert oncologists discuss a patient profile in advanced HCC, evaluating a patient treated with durvalumab plus tremelimumab.

Patients With Intermediate Stage HCC Suitable for TACE

February 20th 2023

Experts review clinical studies evaluating TACE in patients with intermediate stage HCC.

Patients With Intermediate Stage HCC Unsuitable for TACE

February 20th 2023

Expert panelists discuss treatment strategies for patients with intermediate stage hepatocellular carcinoma (HCC) that are unsuitable for transarterial chemoembolization (TACE).

Erdafitinib Data in FGFR+ Cholangiocarcinoma Indicates Utility of NGS in Treatment Selection

February 20th 2023

Shubham Pant, MD, MBBS, discusses significant efficacy and safety data from the RAGNAR trial, how erdafitinib fits into the current treatment paradigm for biliary tract cancers, and the role of next-generation sequencing in the selection of FGFR inhibitors for this patient population.

KEYNOTE-859 Data Show 1.4-Month OS Benefit With Frontline Pembrolizumab Plus Chemo in Advanced HER2– Gastric or GEJ Cancer

February 17th 2023

The addition of pembrolizumab to chemotherapy resulted in a significant and clinically meaningful improvement in overall survival, progression-free survival, and objective response rate vs chemotherapy alone when used as first-line treatment in patients with advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma.

Clinical Scenario: Diagnostic Strategies to Identify Biliary Tract Cancers

February 15th 2023

Centering focus on a patient scenario, panelists break down mainstay diagnostic strategies used to identify biliary tract cancers.

Overview on Biliary Tract Cancers and Their Rising Incidence

February 15th 2023

Expert panelists open their discussion on biliary tract cancers by identifying various subsets and noting the growing incidence of these diseases.

Pembrolizumab Plus Total Neoadjuvant Therapy Improves Long-Term OS in Locally Advanced Rectal Cancer

February 13th 2023

Thomas J. George, MD, FACP, highlights the long-term data from the NRG-GI002 trial, the next steps for exploring subsets of patients who may benefit from the addition of pembrolizumab or veliparib to total neoadjuvant therapy, and what the use of total neoadjuvant therapy has meant for patients with stage II/III locally advanced rectal cancer.

Checkpoint Inhibitors, FGFR Inhibitors Lead to Continued Advancements in Biliary Tract Cancer

February 13th 2023

James Harding, MD, highlighted current and emerging areas of research in biliary tract cancer, including key contributions from TOPAZ-1 and the phase 3 SWOG 1815 trial, the development of immunotherapy and chemotherapy combinations, and continued efforts to utilize personalized medicine in clinical practice.

Dr. Sahin on the Background of the IMbrave 151 Trial in Biliary Tract Cancer

February 11th 2023

Ilyas Sahin, MD, discusses the background and findings of the phase 2 IMbrave 151 trial in advanced biliary tract cancer.

Dr. Walden on the RNA Expression of Homologous Recombination Genes in CRC

February 10th 2023

Daniel Walden, MD, discusses the association of low expression of RNA of wild-type homologous recombination genes and survival in colorectal cancer.

Dr. Friedland on a Multimodal Screening Blood Test to Detect CRC

February 10th 2023

Shai Friedland, MD, discusses a multimodal screening blood test for advanced adenomas in colorectal cancer.

PD-1/VEGFR-2 Inhibitor Combo Shows Durable Responses in Nasopharyngeal Carcinoma

February 10th 2023

The combination of camrelizumab and apatinib led to long-term antitumor activity with manageable toxicities in patients with recurrent or metastatic nasopharyngeal carcinoma.

ODAC Votes in Favor of Continued Development of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer

February 9th 2023

In an 8 to 5 vote, the FDA’s ODAC voted that data from two proposed single-arm trials will provide adequate means of characterizing the risk-benefit profile of dostarlimab for the treatment of patients with dMMR/MSI-H locally advanced rectal cancer.

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

February 9th 2023

Dr D’Amato discusses research in sarcoma and gastrointestinal stromal tumor, incorporating circulating tumor DNA analysis into routine reevaluation of patients with progressive disease, and the importance of establishing a drug’s clinical profile in non–trial target ethnic populations.

Dr. Kundranda on the Sequencing of Second-Line Therapies in HCC

February 9th 2023

Madappa Kundranda, MD, PhD, discusses the sequencing of second-line therapies in hepatocellular carcinoma.

FDA Grants Orphan Drug Designation to Ezurpimtrostat for HCC

February 8th 2023

The FDA has granted an orphan drug designation to ezurpimtrostat, a PPT-1 inhibitor for the treatment of patients with hepatocellular carcinoma.

Investigators Seek Simpler Solution to Treatment Resistance in Esophageal Cancer

February 6th 2023

Although the incidence, location, and histology of esophageal cancer vary globally, patients in the Western World typically develop esophageal cancer in the distal esophagus or at the gastroesophageal junction.

Socioeconomic Factors Are Associated With Disparities in Germline Testing in Pancreatic Cancer

February 5th 2023

Daniel King, MD, PhD, discusses the results of an institutional review evaluating socioeconomic factors associated with disparities for germline genetic testing in patients with pancreatic adenocarcinoma, why germline testing is necessary for thi population, and how he is addressing gaps in germline testing in his own practice.

SWOG 1815 Biomarker Analyses May Identify Biliary Tract Cancer Subsets Who Could Benefit From Nab-Paclitaxel Triplet

February 4th 2023

Rachna T. Shroff, MD, MS, expands on the rationale for evaluating the addition of nab-paclitaxel to gemcitabine/cisplatin in patients with newly diagnosed biliary tract cancers, data presented from SWOG 1815, and how this study may pave the way for future research efforts in the paradigm.